6533b82ffe1ef96bd1295d51
RESEARCH PRODUCT
Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need gor Early Biomarkers snd Cardio- snd Vasculo-Protection in Personalized Therapy
Péter FerdinandyFrancesca MacaioneRosalinda Madonnasubject
Cardiovascular toxicityCardiotoxicitymedicine.medical_specialtyChemotherapyVascular Toxicitybusiness.industryIncidence (epidemiology)medicine.medical_treatmentBiomarkers Omics Cardioprotection Vasculoprotection Cardiotoxicity Vascular Toxicity Anticancer drugsVasculoprotectionCancerOmicsCardioprotectionmedicine.diseaseOmicsAnticancer drugsCardiotoxicityQuality of lifemedicinePersonalized therapyIntensive care medicinebusinessBiomarkersdescription
The use of chemotherapy has largely improved the prognosis of cancer patients in the past two decades. However, the advent of more effective anticancer therapies has led to a higher incidence of cardiovascular toxicity that shows an increased incidence and represents a significant determinant of quality of life and mortality during ongoing treatment and in long-term survivors of cancer. In this setting, the primary objective for cardiologists and oncologists is the early identification of patients at high risk for developing cardiovascular toxicity and the identification of the cardiovascular cardiotoxicity in the earliest stages to personalize cancer therapy, arrange preventive interventions, and implement cardioprotective treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-10-05 |